99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows

On Wednesday, Eli Lilly And Co LLY released detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide.

Weekly tirzepatide (Zepbound and Mounjaro) injections (pooled 5 mg, 10 mg, 15 mg doses) significantly reduced the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight, compared with placebo, over 176 weeks.

Tirzepatide demonstrated sustained average weight loss of 22.9% (15 mg dose) through the three-year treatment period for the efficacy estimandi.

Also Read: Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks

“Individuals treated with tirzepatide lost on average up to 23% of their body weight and maintained this for over three years while benefitting from a substantial decrease in risk of developing type 2 diabetes. In absolute terms, nearly 99% of individuals treated with tirzepatide remained diabetes-free at 176 weeks,” said Ania Jastreboff, director of the Yale Obesity Research Center.

“In the SURMOUNT-1 three-year study of tirzepatide, an average weight reduction of up to 22.9% was accompanied by a hazard ratio of 0.06 for progression to type 2 diabetes. This translates to a risk reduction of 94% and a number needed to treat of nine to prevent one case of diabetes,” said Jeff Emmick, SVP of product development at Eli Lilly.

At 193 weeks, 2.4% of patients on Lilly’s tirzepatide were diagnosed with Type 2 diabetes compared to 13.7% of patients in the placebo group.

In additional endpoints, the study showed an association of tirzepatide treatment with improved glycemic control, cardiometabolic risk factors (including fasting insulin, blood pressure, and lipids), and health-related quality of life sustained through 176 weeks.

A post hoc mediation analysis suggested that approximately half of the observed effect in a delay to onset of type 2 diabetes with tirzepatide was associated with medication-induced weight reduction.

Price Action: LLY stock is down 2.21% at $793.97 at the last check on Thursday.

Read Next:

• Salesforce CEO Marc Benioff Bets Big on Billion Bots

Image by Mohammed_Al_Ali via Shutterstock